Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoglitazone
- Development stage
- Phase 2
- Lead developer
- Metabolic Solutions Development Company
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mitoglitazone (MSDC-0160) is a small molecule insulin sensitizer developed by Metabolic Solutions Development Company for the treatment of type 2 diabetes mellitus. It functions as a selective modulator of the mitochondrial Target of Thiazolidinediones (mTOT), a protein complex in the inner mitochondrial membrane now identified as the Mitochondrial Pyruvate Carrier (MPC). Unlike traditional thiazolidinediones such as pioglitazone, mitoglitazone is designed to be PPAR-sparing, meaning it improves insulin sensitivity and nutrient-sensing pathways without direct activation of the nuclear transcription factor PPARγ. This mechanism is intended to avoid common side effects associated with PPARγ agonists, such as fluid retention and weight gain. In addition to metabolic disorders, mitoglitazone has been investigated for its potential neuroprotective effects in Alzheimer's and Parkinson's diseases.
- Brand names
- Mitoglitazone
- Other names
- mitoglitazone
02
Targets
MPC (Mitochondrial pyruvate carrier)CISD1 (CDGSH iron-sulfur domain-containing protein 1)
Beyond the preview
Go deeper on mitoglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoglitazone.